Search - tctmd.com

Displaying 1 - 20 of 98

Sort: Relevancy | Date

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

September 09, 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

August 31, 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

News Conference News ESC 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

August 29, 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

What’s Going to Be Hot at ESC Congress 2025?

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

Endometriosis and CV Risk: Link Needs Further Attention and Research

News Conference News ESC 2024

Endometriosis and CV Risk: Link Needs Further Attention and Research

Yael L. Maxwell

September 12, 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

News Conference News ESC 2024

New ESC Guidelines on BP and Hypertension Shift Treatment Targets Lower

Yael L. Maxwell

September 04, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

News Conference News ESC 2024

Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events

Michael O'Riordan

September 01, 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

August 31, 2024

Stop-or-Not It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

News Conference News ESC 2024

Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery

August 30, 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

August 30, 2024

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

ESC/EACTS Task Force Recommends Downgrading PCI in Left Main CAD

News Conference News ESC 2023

ESC/EACTS Task Force Recommends Downgrading PCI in Left Main CAD

Michael O'Riordan

September 05, 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

September 01, 2023

ESC Endocarditis Guidelines Get First Update in 8 Years

News Conference News ESC 2023

ESC Endocarditis Guidelines Get First Update in 8 Years

August 31, 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.